Epicardial pacemaker placement in cats is associated with resolution of clinical signs and excellent quality of life.

Objective: To describe complications and outcomes in cats undergoing epicardial pacemaker (EP) implantation for artificial cardiac pacing and to investigate improvement in clinical signs and health-related quality of life (HRQoL) following surgery.

Methods: 39 client-owned cats that underwent EP placement. Medical records of 4 UK-based referral hospitals were searched and data reviewed retrospectively between July 2010 and December 2022.

May Measurement Month 2021: an analysis of blood pressure screening results from Australia.

May Measurement Month (MMM) is a global and national blood pressure (BP) screening campaign initiated by the International Society of Hypertension to improve awareness of BP worldwide. This study reports on the findings of the MMM21 campaign in Australia. Adult participants (≥18 years) were screened through opportunistic sampling across Australia between 1 May and 30 November 2021.

Use of an autologous pericardial patch to repair a post-traumatic caudal vena cava cicatrix in a dog.

Objective: To report the use of a pericardial patch graft to repair a post-traumatic caudal vena cava cicatrix in a dog.

Study Design: Case report.

Animals: A 1 year-old Rottweiler presenting with ascites following presumed blunt thoracic trauma.

Epicardial pacemaker placement is associated with low complication rate and improved quality of life in dogs.

Objective: To describe complications and outcomes in dogs undergoing epicardial pacemaker (EP) implantation, identify factors associated with survival, and investigate improvement in clinical signs and health-related quality of life (HRQoL) following surgery.

Animals: 52 client-owned dogs that underwent EP placement.

Methods: Medical records of 4 UK-based referral hospitals were searched and data reviewed retrospectively between July 2010 and December 2022.

Evidence review and considerations for use of first line genome sequencing to diagnose rare genetic disorders.

Early use of genome sequencing (GS) in the diagnostic odyssey can reduce suffering and improve care, but questions remain about which patient populations are most amenable to GS as a first-line diagnostic test. To address this, the Medical Genome Initiative conducted a literature review to identify appropriate clinical indications for GS. Studies published from January 2011 to August 2022 that reported on the diagnostic yield (DY) or clinical utility of GS were included.